Catestatin peptide ameliorates tauopathy and amyloidogenesis via adrenergic inhibition.
Catestatin (CST), a CgA-derived peptide, is investigated for its role in modulating tauopathy and marked reductions in CST levels and an increase in Pancreastatin (PST) in the hippocampus and cortex of AD brains, as well as in the frontal cortex of CBD and the basal ganglia of PSP.